Abstract
Two patients suffering from benign and one patient suffering from malignant insulinoma experienced frequent incapacitating hypoglycemic attacks which did not respond to treatment with streptozotocin, diazoxide and/or diphenylhydantoin. Dl-propranolol, in dosages ranging from 30–240 mg/day, successfully abolished the symptoms of hypoglycemia, prevented recurrent hypoglycemic attacks, and normalized blood glucose levels concomitant with a reduction in pulse rate to 60/min.The main mechanism of the drug’s effect seems to be the suppression of insulin release. However, other mechanisms may be involved such as increased peripheral insulin resistance. No side effects of treatment with dl-propranolol were noted. In patients suffering from insulinoma who are refractory to other forms of treatment, and for those who need symptomatic relief before surgery, dl-propranolol may play an important therapeutic role.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Neri V., Bartorelli A., Faglia G. L’azione del propranolol sulla glicemia e sull’insulina immunoreattiva in una paziente affetta da insulinoma. Acta Diabetol. Lat. 6: 809, 1969.
Blum I., Doron M., Laron Z., Atsmon A. Prevention of hypoglycemic attacks by propranolol in a patient suffering from insulinoma. Diabetes 24: 535, 1975.
Shaklay M., Aderka D., Blum I., Laron Z., Asherov J., Doron M., Atsmon A., Pinkhas J. Suppression of hypoglycemic attacks and insulin release by propranolol in a patient with metastatic malignant insulinoma. Diabete Metab. 3: 155, 1977.
Blum I., Aderka D., Doron M., Laron Z. A comparison of dl-propranolol and d-propranolol in a patient with malignant insulinoma. N.Engl. J. Med. 299: 487, 1978.
Turner R.C., Oakley N.W., Nabarro J.D.N. Control of basal insulin secretion with special reference to the diagnosis of insulinomas. Br. Med. J. 2: 132, 1971.
Duckworth W.C., Kitabchi A.E. Direct measurement of plasma proinsulin in normal and diabetic subjects. Am. J. Med. 53:418, 1972.
King K.C., Adam P.A.J., Yamaguchi K., Schwartz R. Insulin response to arginine in normal newborn infants and infants of diabetic mothers. Diabetes 23: 816, 1974.
Pi-Sunyer P.X., Van Itallie T.B., Zintel H.A. Insulin stimulatory tests in a patient with islet cell adenoma. Am. J. Surg. 118:95, 1969.
Hales C.N., Randle P.J. Immunoassay of insulin with insulin-antibody precipitate. Biochem. J. 88: 137, 1963.
Quabbe H.J. Modifikation der radioimmunologischen insulin bestimmung nach Hales und Randle. Diabetologia 5: 101, 1969.
Cresto J.C., Lavine R.L., Fink G., Recant L. Gel filtration assay plasma proinsulin; comparison of insulin specific protease and gel filtration assays. Diabetes 23: 505, 1974.
Unger R.H., Aguilar-Parada E., Muller W.A., Eisentraut A.M. Studies in pancreatic alpha cell function in normal and diabetic subjects. J.Clin. Invest. 49:837, 1970.
Scandellari C., Zaccaria M., De Palo C., Sicolo N., Erie G., Federspil G. The effect of propranolol on hypoglycemia. Diabetologia 15:297, 1978.
Woods S.C., Porte O. Neural control of the endocrine pancreas. Physiol. Rev. 54:596, 1974.
Samols E., Weir G.C. Adrenergic stimulation of pancreatic A, B and D cells alpha-adrenergic suppression and beta-adrenergic stimulation of somatostatin secretion, alpha-adrenergic stimulation of glucagon secretion in the perfused dog pancreas. J.Clin. Invest. 63:230, 1979.
Iversen J. Adrenergic receptors and the secretion of glucagon and insulin from the isolated perfused canine pancreas. J.Clin. Invest. 52:2102, 1973.
Cerasi E., Luft B., Efendic S. Effect of adrenergic blocking agents on insulin response to glucose infusion in man. Acta Endocrinol, (kbh.) 69: 335, 1972.
Harrower A.D.B., Nairn I.M., Strong J.A. Effect of propranolol on glucose tolerance in hyperthyroidism. Postgrad. Med. J. 53: 687, 1977.
Ortigosa J.L., Mendoza F., Argote R.M., Garcia G., Cervantes C., Parra A. Propranolol effect on plasma glucose, free fatty acid, insulin and growth hormone in Graves’ disease. Metabolism 25:1201, 1976.
Wright A.D., Barber S.G., Kendall M.J., Poole P.H. Beta adrenoreceptor blocking drugs and blood sugar control in diabetes mellitus. Br. Med. J. 1: 159, 1979.
O’Dea K., Tank C., Kaplovitz H., Marino A.J. Development of insulin sensitivity in rat aorta after chronic propranolol treatment. Eur. J. Pharmacol. 47: 63, 1978.
Exton J.H. Mechanisms involved in alpha-adrenergic effects of catecholamines on liver metabolism. J. Cyclic Nucleotide Res. 5: 277, 1979.
Ohneda A., Matsuda K., Horigome K., Ishii S., Yanbe A., Maruhama Y. Plasma glucagon in insulinoma. Acta Diabetol. Lat. 14:219, 1977.
Gerich J.E., Langlois M., Noacco C., Schneider V., Forsham P.H. Adrenergic modulation of pancreatic glucagon secretion in man. J.Clin. Invest. 53: 1441, 1974.
Harvey W., Faloona G., Unger R. Effect of adrenergic blockade on exercise-induced hyperglucagonemia. Clin. Res. 20: 752A, 1972.
Walter R.M., Dudl R.J., Palmer J.P., Ensinck J.W. The effect of adrenergic blockade on the glucagon response to starvation and hypoglycemia in man. J. Clin. Invest. 54:1214, 1974.
Leonetti G., Zanchetti A. Studies of the absorption and removal of propranolol in hypertensive patients during therapy. Circulation 52: 313, 1975.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Blum, I., Rusecki, Y., Doron, M. et al. Evidence for a therapeutic effect of dl-propranolol in benign and malignant insulinoma: report of three cases. J Endocrinol Invest 6, 41–45 (1983). https://doi.org/10.1007/BF03350559
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03350559